Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Investor Presentation (April 2024)
30 slides from Morepen Laboratories's investor presentation, Apr 15, 2024
Slide 1: Corporate Presentation filing cover letter to NSE and BSE
Date: 15.04.2024 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Corporate Presentation of Morepen Laboratories Limited (‘the
Slide 2: Burnol trademark note
Burnol* For Burnol -the trademark for the product has not been assigned to us and is subject to our ongoing litigation
Slide 3: Safe Harbour
Safe Harbour This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited (“Company”) together with its subsidiaries, as applicable (together, with the Company, the “Group”) only, without regard to any specific objectives, suitability, fina
Slide 4: Contents
Contents 1 Company overview 2 Key strengths 3 Strategies 4 Financial Information 5 Annexure 3
Slide 5: Company Overview
1 Indian Pharmaceutical company with range of API, Medical Devices, Formulations and Over the counter (OTC) products Company Overview
Slide 6: Indian Pharmaceutical Company with presence across 4 segments
Indian Pharmaceutical Company with presence across 4 segments Company Overview Corporate Structure Incorporated in 1984 by Mr. KB Suri, Morepen Laboratories Limited has rapidly expanded its Flagship company houses API, Medical presence and has become a prominent player in the pharmaceutical market
Slide 7: Business profile
Business profile BUSINESS SEGMENTS Select high value APIs such as Loratadine, Desloratadine, Montelukast, Atorvastatin, API MEDICAL DEVICES Rosuvastatin, Fexofenadine* 1000+ Products present in portfolio FORMULATIONS OVER THE COUNTER 6 *Source: Industry report
Slide 8: Changing business mix and moving towards medical devices
Changing business mix and moving towards medical devices Breakup of Revenue from Operations 6.91% 6.57% 5.47% 10.36% 12.65% 12.84% 53.77% FY21 FY23 9 months ended on INR 1,18,805.64 INR 1,41,753.00 December 31, 2023 lakhs 58.54% lakhs 57.71% INR 1,26,735.90 24.19% 23.07% lakhs 27.92% API Medical dev
Slide 9: Key Strengths
2 Creating category leadership across segments Key Strengths
Slide 10: Key Strengths
Key Strengths Legacy of 39+ years 1 One the leading developers and manufacturers of select high value APIs* One of the leading blood glucose monitor and blood pressure monitor brands in India* Creating brands 6 and leadership 2 across businesses NIL-483 in the last 2 US FDA inspections in it
Slide 11: Leading manufacturer in API and Medical devices
Leading manufacturer in API and Medical devices 1 Active Pharmaceutical Ingredient (API)* Medical devices *FY24E Company Company Company 35% 26% 44% One of the Leading 1st in Market share 1st in Market share 1st in Market share Blood glucose monitor Others Others Others brand in India with 19% by
Slide 12: Expanding customer base in medical devices
Expanding customer base in medical devices 1 No. of Blood Glucose monitor sold Blood Glucose monitor and Blood Glucose (BG) Test Strips (million) 2.17 2.12 1.91 1.69 7.90 million Blood 1,045.47 million Blood FY21 FY22 FY23 9 months ended on Glucose Monitor sold glucose monitor strips Dec 31, 2023 (F
Slide 13: Portfolio catering to wide range of therapies | API
Portfolio catering to wide range of therapies| API 1 Anti-Histaminic Cardiac Anti- Diabetic LORATADINE ATORVASTATIN SITAGLIPTIN Cholesterol reduction DESLORATADINE SAXAGLITIN ROSUVASTATIN Cholesterol reduction LINAGLIPTIN Anti-Asthmatic/Allergy OLMESARTAN ANTI- HYPERTENSIVE DAPAGLIFLOZIN MONTELUKAST
Slide 14: Manufacturing led by focus on quality
Manufacturing led by focus on quality…. 2 API manufacturing facility – Baddi and Masulkhana US FDA ANVISA WHO- GMP NIL-483: for last 2 inspections for its Baddi Masulkhana facility Both Baddi and facility – 2018* & 2023*and last inspection for Masulkhana facility its Masulkhana facility – 2018*) * Y
Slide 15: Regulatory framework and Intellectual Property
….and regulatory framework 2 Intellectual Property* 155 55 252 PATENTS FILED PATENTS GRANTED^ DMFs Filings 26 9 US DMFs European Filings *above approvals are as on 31st March 2024 ^ included ceased and expired 14
Slide 16: Manufacturing base to produce range of products
Manufacturing base to produce range of products 3 Manufacturing facilities Capacity and Utilization Installed Capacity-Annual 9 months Business unit I started in Business unit III started in ended on Business unit IV UoM FY 21 FY 22 FY 23 1985 & merged with unit 1996 & unit V started in December sta
Slide 17: Distribution through distributor and retail network
Distribution through distributor and retail network 4 North region Central region Distributor – 1,624 Distributor – 781 Super stockist + CFA’s – 9 Super stockist + CFA’s – 5 Retailers/Chemists + Doctors – 98.4K Retailers/Chemists + Doctors – 53.3K Western India North east region Distri
Slide 18: Revenue from Operations - API Business
Customer network across 80+ countries 5 Revenue from Operations - API Business MENA S. America 3.25% 4.43% USA MENA 19.16% 12.12% USA 12.00% S. America 4.65% Europe India 9 months ending FY23 December 2023 - Europe 18.19% 32.20% INR 81,792.23 INR 68,140.34 lakhs 14.47% lakhs India 30.92% Asia 22.13%
Slide 19: Board supported by management team with years of experience
Board supported by management Team with years of experience 6 Sanjay Suri Manoj Joshi Bhupender Raj Sukhcharan Singh Whole Time Director Independent Director Wadhwa Independent Director Independent Director Chartered Accountant Praveen Kumar Dutt Savita Ajay Sharma Vipul Srivastava Mr. Sushil Suri I
Slide 20: Key Strategies
Strive to become a key 3 Key Strategies brand across API, Medical devices, Formulations and OTC
Slide 21: Expansion playbook
Expansion playbook Expansion of API and formulations capacities Expand the API facility capacity Expanding formulation manufacturing with international standards Building capacity of Blood glucose monitor strips Expand geographical footprint and increase Building capacity for end to end manufact
Slide 22: Financial and Operating Metrics
4 Financial and Operating Metrics
Slide 23: Financial and operational metrics
Financial and operational metrics Rs. in Lakhs 9 months ended on 9 months ended on Consolidated performance FY21 FY22 FY23 December 31, 2022 December 31, 2023 Revenue from operations 1,18,805.64 1,54,682.69 1,41,753.00 1,05,384.48 1,26,735.90 Other income 1,206.89 1,030.72 613.34 301.06 972.78 EBITD
Slide 24: Consolidated Income Statement
Consolidated Income Statement Rs. in Lakhs 9 months ended on 9 months ended on Particulars FY21 FY22 FY23 December 31, 2022 December 31, 2023 Operating Revenue 1,18,805.64 1,54,682.69 1,41,753.00 1,05,384.48 1,26,735.90 Other Income 1,206.89 1,030.72 613.34 301.06 972.78 Total Income 1,20,012.53 1,5
Slide 25: Consolidated Balance Sheet
Consolidated Balance Sheet Rs. in Lakhs Particulars as on March'21 March'22 March'23 December’ 22 December’ 23 Equity Share Capital 8,995.86 9,555.86 10,222.71 10,222.71 10,222.71 Reserves 33,479.12 48,300.26 65,068.10 64,346.69 71,875.31 Total Equity 42,474.98 57,856.12 75,290.81 74,569.40 82,098.0
Slide 26: Annexure
a MOREPEN | Annexure
Slide 27: Formulations product portfolio
Morepen | Formulations Product portfolio Formulations Saltum Intebact Pregamust Metored Metmore -500 Klarim Ryhtmix Ecilop Metmore -1000 Bio- Rhythm 26
Slide 28: OTC product portfolio
Morepen | OTC product portfolio Cold Tabs Fever Pregnancy OTC PRODUCTS Pain- X O.R.S Oral Care HEALTH & NUTRITION Lemolate C- Candy 27
Slide 29: Online product portfolio
Morepen | Online product portfolio NEW ONLINE RANGE ONLINE RANGE LAUNCHED AT WWW.HEALTH.DRMOREPEN.COM Multi- Vitamins Apple cider Collagen Muscle Food Sexual Wellness Iron & Zinc Weight Gainer Garcinia Biotin+ Gokshura Milk Thistle+ Omega 3 Stress & Sleep Testo Booster COD Liver 28
Slide 30: Thank You
Ve Frorepert MOREPEN THANK YOU LT
Morepen Laboratories — Investor Presentation (April 2024) on 6ix